| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
29,280,000 as of 6/30 |
| Market
Cap: |
321.20(M) |
| Last
Volume: |
467,093 |
Avg
Vol: |
151,442 |
| 52
Week Range: |
$2.3 - $12.23 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 5.8 |
| Insider 3/6 Months : 6.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile Albany Molecular Research is a contract research and manufacturing organization providing customers integrated drug discovery, development, and manufacturing services. Co. has two segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small Scale Manufacturing (DDS). Co.'s LSM activities include pilot to commercial scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing and its remaining activities, including drug lead discovery, optimization, drug development, and small scale commercial manufacturing represent its DDS business segment.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,000 |
30,000 |
44,100 |
| Total Buy Value |
$0 |
$50,000 |
$126,000 |
$160,295 |
| Total People Bought |
0 |
1 |
3 |
6 |
| Total Buy Transactions |
0 |
1 |
3 |
7 |
| Total Shares Sold |
17,474 |
20,442 |
25,822 |
32,292 |
| Total Sell Value |
$185,289 |
$209,277 |
$225,101 |
$243,874 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
11 |
14 |
19 |
26 |
| End Date |
2013-02-23 |
2012-11-22 |
2012-05-24 |
2011-05-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-05-22 |
4 |
S |
$10.97 |
$82,275 |
D/D |
(7,500) |
57,090 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-05-22 |
4 |
OE |
$2.93 |
$21,975 |
D/D |
7,500 |
64,590 |
|
- |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-05-10 |
4 |
S |
$10.40 |
$12,480 |
D/D |
(1,200) |
32,580 |
|
2% |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-03-19 |
4 |
S |
$9.91 |
$1,784 |
D/D |
(180) |
33,780 |
|
-14% |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-03-19 |
4 |
S |
$9.91 |
$2,557 |
D/D |
(258) |
57,090 |
|
-14% |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-03-18 |
4 |
S |
$9.98 |
$2,555 |
D/D |
(256) |
57,348 |
|
-10% |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-03-18 |
4 |
S |
$9.98 |
$2,485 |
D/D |
(249) |
33,960 |
|
-10% |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-03-13 |
4 |
S |
$10.69 |
$9,108 |
D/D |
(852) |
57,604 |
|
-2% |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-03-12 |
4 |
S |
$10.75 |
$7,278 |
D/D |
(677) |
34,209 |
|
-1% |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-03-12 |
4 |
S |
$10.73 |
$18,942 |
D/D |
(1,764) |
58,456 |
|
-1% |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-03-11 |
4 |
S |
$10.25 |
$36,265 |
D/D |
(3,538) |
60,220 |
|
-5% |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-03-07 |
4 |
S |
$9.56 |
$9,560 |
D/D |
(1,000) |
34,886 |
|
-10% |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2013-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,200 |
2,759,650 |
|
- |
|
| D Ambra Constance M |
10% Owner |
– – • |
2013-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,200 |
2,686,318 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-02-22 |
4 |
S |
$8.18 |
$8,049 |
D/D |
(984) |
63,758 |
|
-36% |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-02-22 |
4 |
S |
$8.18 |
$8,049 |
D/D |
(984) |
35,886 |
|
-36% |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-02-19 |
4 |
S |
$7.89 |
$7,890 |
D/D |
(1,000) |
36,870 |
|
-33% |
|
| Marth William S |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
28,291 |
|
- |
|
| Jordan Veronica Gh |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
29,147 |
|
- |
|
| Ryan Una S |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
26,084 |
|
- |
|
| Roth Arthur J |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
33,104 |
|
- |
|
| Oconnor Kevin |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
30,420 |
|
- |
|
| Leung Gabriel |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
25,321 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2013-01-31 |
4 |
A |
$5.99 |
$159,729 |
D/D |
26,666 |
2,769,850 |
|
- |
|
| Henderson Lori M |
VP, general counsel |
• – – |
2013-01-31 |
4 |
A |
$5.99 |
$69,879 |
D/D |
11,666 |
49,440 |
|
- |
|
258 Records found
|
|
Page 1 of 11 |
|
|
0.23 (2.05%) 
